上海莱士血液制品股份有限公司 2020 年年度报告 披露日期：2021 年 04 月 23 日 上海莱士血液制品股份有限公司 2020 年年度报告全文 1 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 公司负责人陈杰先生、主管会计工作负责人刘峥先生及会计机构负责人(会 计主管人员)赵曦女士声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告所涉及的公司发展情况是基于当前形势的预计，不构成公司对投资 者的实质性承诺，敬请投资者注意投资风险。 | --- | |--------------------------------------------------------------------------------------| | | | 公司近期不存在可能对公司生产经营状况、财务状况和持续盈利能力有严 | | 重不利影响需作特别提示的风险因素。（公司可能面临的风险见本年度报告 | | 四节 • 经营情况讨论与分析 • 九、公 ...

上海莱士血液制品股份有限公司 2020 年半年度报告 披露日期：2020 年 08 月 27 日 上海莱士血液制品股份有限公司 2020 年半年度报告全文 1 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 公司负责人陈杰先生、主管会计工作负责人刘峥先生及会计机构负责人(会 计主管人员)赵曦女士声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告所涉及的公司发展情况是基于当前形势的预计，不构成公司对投资 者的实质性承诺，公司可能存在产品潜在的安全性风险、原材料供应不足的风 险、血浆成本存在上升风险及商誉减值风险等，具体内容详见本报告"第四节 经 营情况讨论与分析"之"十、公司面临的风险和应对措施"。敬请广大投资者注意 投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 上海莱士血液制品股份有限公司 2020 年半年度报告全文 目录 | --- | |------------------------------ ...

Financial Performance - The company's revenue for Q1 2020 was CNY 731,878,768.03, representing a 25.18% increase compared to CNY 584,661,667.88 in the same period last year[5]. - Net profit attributable to shareholders was CNY 310,662,433.63, up 41.97% from CNY 218,820,740.00 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 326,564,932.05, reflecting a 60.21% increase from CNY 203,831,112.72 in the previous year[5]. - The net cash flow from operating activities surged by 317.19% to CNY 508,223,559.58, compared to CNY 121,820,788.59 in the same quarter last year[5]. - Basic earnings per share for the period were CNY 0.056, up 27.27% from CNY 0.044 in the same period last year[5]. - The company reported a significant increase in revenue for Q1 2020, with a year-over-year growth of 15%[28]. - The net profit for the first quarter reached CNY 309,061,714.58, up 41.8% from CNY 217,801,818.06 year-over-year[50]. - The total comprehensive income for the period was CNY 322,819,022.03, compared to CNY 217,801,818.06 in the previous year, indicating a growth of 48.2%[50]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 25,397,011,638.49, a 114.27% increase from CNY 11,853,051,145.30 at the end of the previous year[5]. - The company's cash and cash equivalents increased by 34.87% to RMB 1,937,339,159.31 due to cash received from sales during the reporting period[12]. - Long-term equity investments surged by 3717.25% to RMB 13,643,996,807.28, primarily due to the completion of a major asset restructuring project[12]. - The company's total equity increased by 35.50% to RMB 6,740,787,907.00 following the issuance of shares during the asset restructuring[12]. - The company's total liabilities decreased to CNY 337,675,206.30 from CNY 361,950,678.56, showing a reduction in financial obligations[43]. - The equity attributable to shareholders of the parent company rose to CNY 25,048,532,876.16 from CNY 11,478,696,191.66, indicating a substantial increase in shareholder value[44]. Shareholder Information - The company reported a total of 129,602 common shareholders at the end of the reporting period[9]. - Major shareholders include GRIFOLS, S.A. with 26.20% ownership and Keri Tiancheng Investment Holding Co., Ltd. with 22.93% ownership[9]. - The company distributed a cash dividend of 3.034624 RMB per 10 shares (tax included) for the first quarter of 2020[16]. Investment and Expansion Plans - The company plans to invest 2 billion RMB in the construction of a southern headquarters and testing center in Changsha, which is crucial for enhancing production capabilities[18]. - The company intends to invest CNY 520.2 million to build a global production and operation base at its existing facility[23]. - The company has allocated a budget of 50 million RMB for research and development in innovative blood products[28]. - The company is expanding its market presence, targeting new regions in Southeast Asia for potential growth[28]. Corporate Governance and Compliance - The company confirmed that there are no significant legal or administrative penalties affecting its operations in the last 36 months, ensuring compliance with relevant laws and regulations[30]. - The company has not engaged in any unauthorized guarantees for its controlling shareholders or actual controllers in the last 12 months[30]. - The company has committed to maintaining the stability of its control over the board and management team, ensuring substantial influence over corporate governance[29]. - The company has ensured that all provided materials for the major asset restructuring are true, accurate, and complete, with no significant omissions or misleading information[30]. - The management team possesses the necessary qualifications and has not violated any legal or regulatory requirements[31]. Risk Management and Legal Matters - The company has recognized a full bad debt loss for the unpaid amount from Shenzhen Xifeng, which may impact its financial performance[26]. - The company has not faced any significant litigation or arbitration cases that could affect its ongoing operations[30]. - The company has committed to strict compliance with regulations regarding share reduction during the restructuring period[31]. Operational Performance - The company reported a strong operational performance, with no significant legal or regulatory issues in the past three years[31]. - The company has maintained a good operational status and is not facing any bankruptcy or dissolution risks[31]. - The company aims to enhance operational management and internal controls to improve efficiency and reduce operational costs[32]. Related Party Transactions - The company has established measures to ensure compliance with relevant laws and regulations regarding related party transactions[33]. - The company will ensure that any related party transactions are conducted fairly and transparently[33]. - The company has committed to avoiding related party transactions that could harm the interests of minority shareholders[36]. Future Outlook - The company provided a positive outlook for the remainder of 2020, projecting a revenue growth of 10-15% for the full year[28]. - New product development initiatives are underway, with two new blood products expected to launch by Q3 2020[28]. - The company is focusing on enhancing its digital platforms to improve customer engagement and streamline operations[28].

Financial Performance - Operating revenue for the third quarter reached CNY 618,652,657.15, representing a 38.01% increase year-on-year[3] - Net profit attributable to shareholders was CNY 192,963,379.31, with a year-to-date net profit of CNY 605,949,573.08[3] - The company reported a 93.80% increase in net profit attributable to shareholders after deducting non-recurring gains and losses, totaling CNY 196,502,150.24 for the quarter[3] - The net cash flow from operating activities increased by 113.49% to CNY 276,544,871.39 for the quarter[3] - The weighted average return on equity rose by 5.63 percentage points to 1.70%[3] - Operating revenue rose by 35.96% to RMB 1,915,776,578.49 from RMB 1,409,036,172.61 year-on-year, driven by significant growth in blood product sales[10] - The company reported a significant increase in revenue for Q3 2019, reaching RMB 1.2 billion, representing a year-over-year growth of 15%[30] - The company achieved a net profit of RMB 300 million in Q3 2019, which is a 20% increase compared to the same period last year[30] Assets and Liabilities - Total assets increased by 3.72% to CNY 11,811,234,654.75 compared to the end of the previous year[3] - The company's total assets increased to ¥11,348,076,897.27, compared to ¥11,100,526,576.46 in the previous year, reflecting a growth of 2.2%[46] - The total liabilities decreased to CNY 329,717,354.68 from CNY 495,179,551.50, a reduction of approximately 33.4%[41] - The company's equity attributable to shareholders rose to CNY 11,469,455,712.23 from CNY 10,877,578,793.87, an increase of about 5.4%[42] - As of September 30, 2019, total current assets amounted to CNY 4,406,007,485.19, an increase from CNY 3,912,440,675.85 as of December 31, 2018, representing a growth of approximately 12.6%[40] Cash Flow - The net cash flow from operating activities surged by 189.01% to RMB 630,381,042.19, attributed to increased cash receipts from sales[10] - The cash flow from operating activities was CNY 2,003,553,188.19, an increase from CNY 1,520,819,185.80 in the prior year, indicating improved cash generation[58] - The ending balance of cash and cash equivalents was ¥1,291,041,704.23, up from ¥867,642,126.74 at the end of Q3 2018, marking an increase of approximately 48.7%[60] Shareholder Information - The total number of shareholders at the end of the reporting period was 110,402, with the top ten shareholders holding significant stakes[6] - The largest shareholder, Keri Tiancheng Investment Holdings Co., Ltd., holds 31.81% of the shares[6] - The company plans to distribute dividends amounting to at least 10% of the distributable profits each year for the next three years, with a cumulative distribution of no less than 30% of the average distributable profits over the three years[34] Investment and Restructuring - The company is planning a major asset restructuring involving the acquisition of 100% equity of Tiancheng International, with a financing cap of 10% of the transaction amount[14] - The restructuring process involves multiple intermediaries and is complicated by cross-border elements, requiring extensive due diligence[16] - The company has engaged various financial and legal advisors to ensure compliance and thoroughness in the restructuring process[16] - The company successfully completed a major asset restructuring, maintaining investor interests and avoiding significant impacts on stock prices[17] - The company received inquiries from the Shenzhen Stock Exchange regarding the restructuring plan, indicating the complexity of the process[18] Research and Development - Research and development expenses for Q3 2019 were ¥20,066,173.27, an increase of 30.0% compared to ¥15,337,369.68 in the same period last year[47] - The company is investing in new product development, focusing on innovative blood products that are expected to launch in Q2 2020[32] Compliance and Governance - The company is committed to complying with all relevant regulations during the establishment of the new plasma collection station[22] - The company has a strategy to minimize related party transactions and ensure fair pricing to protect the interests of minority shareholders[33] - The company has conducted multiple investor relations activities, including on-site research, to maintain transparency and communication with stakeholders[37]

Financial Performance - The company reported a significant increase in revenue, with a total of RMB 1.2 billion for the first half of 2019, representing a year-on-year growth of 15%[6]. - The company's operating revenue for the reporting period was ¥1,297,123,921.34, representing a 35.01% increase compared to ¥960,763,673.08 in the same period last year[9]. - Net profit attributable to shareholders was ¥412,986,193.77, a significant turnaround from a loss of ¥847,127,306.16 in the previous year, marking a 148.75% increase[9]. - The net cash flow from operating activities reached ¥353,836,170.80, up 299.44% from ¥88,582,955.72 in the same period last year[9][10]. - Basic and diluted earnings per share were both ¥0.08, compared to a loss of ¥0.17 per share in the previous year, reflecting a 147.06% improvement[9]. - The total comprehensive income for the first half of 2019 was ¥403,801,423.01, compared to a comprehensive loss of ¥850,461,977.45 in the previous year[149]. Revenue Breakdown - In the first half of 2019, the company's blood product sales revenue reached RMB 1,297,123,921.34, a year-on-year increase of 35.01%[32]. - The sales revenue from albumin was RMB 471,356,397.04, accounting for 36.34% of total revenue, with a year-on-year growth of 13.53%[38]. - The sales revenue from immunoglobulin (静丙) was RMB 402,378,009.23, showing a significant increase of 50.23% year-on-year[38]. - The revenue from other blood products reached RMB 423,389,515.07, marking a year-on-year growth of 52.43%[38]. Market Expansion and Strategy - The company is expanding its market presence by establishing new partnerships in Southeast Asia, aiming to increase international sales by 25% in the next fiscal year[6]. - A strategic acquisition of a local competitor is in progress, which is expected to enhance market share by 15% post-integration[6]. - The company is actively pursuing an overseas acquisition of a 45% stake in GDS, which is essential for the blood product ecosystem strategy and quality control[22]. - The company has successfully integrated its acquisitions of Zhengzhou Laisi, Tonglu Biology, and Zhejiang Haikang, significantly enhancing its product variety and profitability[22]. Operational Efficiency and Cost Management - The company is focusing on enhancing operational efficiency, targeting a reduction in production costs by 10% through process optimization[6]. - The company has identified potential risks, including rising plasma costs, which could impact profit margins by approximately 5% if not managed effectively[2]. - The management emphasized the importance of regulatory compliance and risk management strategies to mitigate potential operational risks[2]. Research and Development - New product development includes the launch of a novel immunoglobulin product, projected to generate RMB 300 million in sales within the first year[6]. - Research and development investment for the first half of 2019 was RMB 47,949,151.14, an increase of 14.05% year-on-year[34]. - The company is focusing on research and development of new technologies to improve its product line and operational efficiency[168]. Financial Position and Assets - Total assets at the end of the reporting period were ¥11,645,030,134.68, a 2.26% increase from ¥11,387,344,824.04 at the end of the previous year[9]. - The net assets attributable to shareholders increased by 3.72% to ¥11,282,681,427.51 from ¥10,877,578,793.87 at the end of the previous year[9]. - Cash and cash equivalents increased by 20.50% compared to the beginning of the period, primarily due to increased cash received from sales during the reporting period[24]. Shareholder and Dividend Policy - No cash dividends will be distributed to shareholders for the current fiscal year, as the company aims to reinvest profits into growth initiatives[2]. - The company has committed to cash dividends of no less than 10% of the distributable profits for each year from 2018 to 2020, with a cumulative distribution of at least 30% of the average annual distributable profits over the three years[71]. Environmental Compliance - The company has not experienced any pollution incidents or legal disputes during the reporting period and has not faced administrative penalties for environmental law violations[99]. - The company plans to conduct daily self-inspections of wastewater and noise measurements every 10 days, with regular third-party assessments for water, air, and noise pollution[97]. Corporate Governance and Compliance - The company operates under strict regulatory compliance, ensuring all financial reporting adheres to the relevant disclosure rules set by the China Securities Regulatory Commission[178]. - The company has established a long-term commitment to avoid related party transactions and ensure fair pricing in any transactions with its subsidiaries[71]. Stock and Shareholder Information - The total number of common shareholders at the end of the reporting period was 98,422[129]. - The largest shareholder, Keri Tiancheng Investment Holdings Co., Ltd., holds 31.81% of shares, totaling 1,582,529,564 shares[129]. - The company’s stock has been suspended since August 23, 2018, and this suspension is expected to last no more than three months to ensure accurate and complete disclosure of restructuring information[109].

Financial Performance - The company's operating revenue for Q1 2019 was ¥584,661,667.88, representing an increase of 84.15% compared to ¥317,494,846.37 in the same period last year[5]. - Net profit attributable to shareholders was ¥218,820,740.00, a significant turnaround from a loss of ¥689,320,030.30 in the previous year, marking an increase of 131.74%[5]. - The net profit after deducting non-recurring gains and losses reached ¥203,831,112.72, up 188.90% from ¥70,554,797.17 in the prior year[5]. - The net cash flow from operating activities improved to ¥121,820,788.59, a 291.15% increase from a negative cash flow of ¥63,729,670.26 in the same period last year[5]. - Basic earnings per share were ¥0.04, compared to a loss of ¥0.14 per share in the same quarter last year, reflecting an increase of 128.57%[5]. - The company reported a significant increase in revenue, with a year-over-year growth of 15% in Q1 2019, reaching approximately 1.5 billion RMB[36]. - The company has set a future outlook with a revenue guidance of 6 billion RMB for the full year 2019, representing a 10% increase from 2018[36]. - The company reported a total profit of CNY 259,877,256.92 for Q1 2019, compared to a total loss of CNY 804,541,814.07 in the previous year[52]. Assets and Liabilities - Total assets at the end of the reporting period were ¥11,430,323,141.44, a slight increase of 0.38% from ¥11,387,344,824.04 at the end of the previous year[5]. - The net assets attributable to shareholders increased by 2.01% to ¥11,096,399,533.87 from ¥10,877,578,793.87 at the end of the previous year[5]. - The company's total liabilities decreased to CNY 1,286,347,611.15 from CNY 1,454,207,714.57 year-over-year, reflecting improved financial health[121]. - Current liabilities decreased to CNY 252,502,097.41 from CNY 424,601,276.49, a significant reduction of approximately 40.5%[46]. - The company's total liabilities decreased to CNY 320,356,050.84 from CNY 495,179,551.50, a significant decline of about 35.3%[46]. Shareholder Information - The total number of shareholders at the end of the reporting period was 115,179, with the top two shareholders holding 62.14% of the shares[8]. - The company has committed to a share buyback program, aiming to repurchase up to 10 million shares over the next 12 months to enhance shareholder value[36]. - The company’s major shareholder, Xu Jun, plans to increase his shareholding by investing between RMB 3 million and RMB 5 million, demonstrating confidence in the company's future[39]. Investment and Expansion Plans - The company is planning a major asset restructuring to acquire 100% equity of Tiancheng International, with a financing cap of 10% of the transaction amount[18]. - The company plans to invest a total of RMB 2 billion in the construction of the Southern Headquarters and Inspection Center in Changsha, which includes a headquarters building, smart factory, R&D center, and inspection center[29]. - The company is exploring investment opportunities in the healthcare sector, particularly in the context of national policies promoting tiered diagnosis and treatment systems[27]. - The company has been expanding its plasma collection network, with new stations approved in Hunan and Shandong provinces to enhance its operational capacity[28]. Research and Development - Research and development expenses for Q1 2019 were CNY 23,682,589.52, an increase from CNY 17,600,287.21 in the same quarter last year, indicating a rise of 34.5%[51]. - The company is actively pursuing partnerships with research institutions to accelerate innovation in blood product technologies[36]. - New product development includes the launch of a novel blood product expected to enter the market by Q3 2019, which is anticipated to drive additional revenue growth[36]. Regulatory and Compliance - The company received a feedback notice from the China Securities Regulatory Commission regarding its asset restructuring application, requiring a written response within 30 working days[25]. - The company has committed to avoiding related party transactions that could harm the interests of minority shareholders, ensuring fair pricing and conditions[39]. - The company has engaged multiple advisory firms for the restructuring, including Shenwan Hongyuan Securities and KPMG[20]. Cash Flow and Financial Management - The cash flow from operating activities generated a net inflow of ¥121,820,788.59, recovering from a net outflow of ¥63,729,670.26 in the previous period[57]. - The company reported a significant increase in cash flow from operating activities compared to the previous period, indicating improved operational efficiency[130]. - The company incurred financial expenses of ¥2,053,542.96, a decrease from ¥7,354,084.51 in the previous period, indicating improved financial management[54]. Market Performance - User data showed a 20% increase in active users compared to the previous quarter, indicating strong customer engagement and retention[36]. - The company is actively pursuing market expansion, with plans to open three new plasma collection centers by the end of 2019, which is expected to increase plasma supply by 30%[106]. - A strategic acquisition of a smaller biotech firm was announced, which is expected to enhance the company's R&D capabilities and product offerings[36].

Financial Performance - The company reported a significant increase in revenue, reaching RMB 1.2 billion, representing a growth of 15% year-over-year[2]. - The company's operating revenue for 2018 was CNY 1,804,235,399.91, a decrease of 6.41% compared to CNY 1,927,748,425.11 in 2017[12]. - The net profit attributable to shareholders for 2018 was a loss of CNY 1,518,397,022.03, representing a decline of 281.66% from a profit of CNY 835,828,588.31 in 2017[12]. - The gross profit margin for the main business of blood products increased to 66.74%, up 2.83% from 63.91% in the previous year[31]. - The revenue from blood products was CNY 1.80 billion, accounting for 100% of total revenue, with a year-on-year decrease of 5.80%[36]. - The company reported a basic earnings per share of -CNY 0.31 for 2018, a decline of 282.35% from CNY 0.17 in 2017[12]. - The company experienced significant non-recurring losses in 2018, totaling CNY -1,673,103,242.54, compared to a profit of CNY 220,428,151.45 in 2017[15]. Market Expansion and Product Development - User data indicated that the number of plasma collection stations increased to 30, contributing to a 20% rise in plasma collection volume[3]. - The company is expanding its market presence by entering two new provinces, aiming to increase market share by 5% in the next fiscal year[2]. - New product development includes the launch of a new immunoglobulin product, expected to generate an additional RMB 200 million in revenue[3]. - The company has a diverse product portfolio with 7 products from Shanghai Laishi, 4 from Zhengzhou Laishi, 8 from Tonglu Biology, and 4 from Zhejiang Haikang[22]. - The company is recognized as one of the largest blood product manufacturers in China, focusing on the production and sale of blood products[17]. Research and Development - The company plans to invest RMB 100 million in R&D for new blood products over the next three years[3]. - The company continued to enhance its research and development capabilities, focusing on improving product structure and increasing the comprehensive utilization rate of plasma[32]. - The company is currently working on several R&D projects, including IVIG process improvements and the development of activated prothrombin complex[50]. Acquisitions and Strategic Initiatives - A strategic acquisition of a 89.77% stake in Tonglu Biological was completed, enhancing the company's product portfolio[5]. - The company has successfully acquired Zhengzhou Laishi, Tonglu Biology, and Zhejiang Haikang, enhancing its competitive edge and profitability[23]. - The company is exploring overseas mergers and acquisitions, aiming to enhance its blood product quality control through strategic partnerships[23]. - The company initiated a major asset restructuring project in February 2018, aiming to acquire 45% equity in GDS, which is crucial for quality control in blood product safety[30]. Financial Management and Shareholder Returns - No cash dividends or stock bonuses will be distributed to shareholders for the fiscal year 2018[2]. - The company has established a shareholder return plan for 2018-2020, ensuring clarity in dividend standards and procedures[95]. - The company did not propose any cash dividend distribution plan for the 2018 fiscal year despite having positive distributable profits[100]. - The company approved a cash dividend of RMB 0.17 per 10 shares, totaling RMB 84,568,575.68 distributed to shareholders for the 2017 fiscal year[99]. Regulatory and Compliance Issues - The company faces potential risks related to regulatory changes in the blood product industry, which could impact future operations[2]. - The management emphasized a commitment to maintaining high-quality standards in production to ensure compliance with international regulations[3]. - The regulatory environment remains stringent, with strict controls on the establishment of new plasma collection stations and the import of blood products[86]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities, with COD emissions monitored at 300 ppm[127]. - Shanghai Laishi constructed a wastewater treatment station with a capacity of 600 m³/d, operating continuously[128]. - Both companies have established emergency response plans for environmental incidents, with Shanghai Laishi's plan initiated in September 2016[132]. Stock and Shareholder Structure - The total number of ordinary shareholders at the end of the reporting period was 100,025, a decrease from 115,179 in the previous month[187]. - The shareholding structure shows that Koryo Tiancheng Investment Holding Co., Ltd. holds 31.81% of shares, totaling 1,582,529,564 shares, with a decrease of 13,000,000 shares during the reporting period[187]. - The company’s independent directors have been in their positions since April 6, 2016, ensuring continuity in governance[200]. Future Outlook and Strategic Goals - The company aims to enhance its core competitiveness and sustainable development capabilities through both self-built and expanded plasma stations, focusing on increasing the plasma collection rate and exploring unique urban plasma station constructions[89]. - The company plans to increase R&D investment significantly, aiming for breakthroughs in key product processes and registrations, with a focus on innovation-driven development[91]. - The company aims to leverage synergies in technology research and development, production, and sales through collaboration with BPL and Biotest to enhance its position in the global blood products industry[168].